ZENTALIS PHARMACEUTICALS INC (ZNTL)

US98943L1070 - Common Stock

12.43  +0.12 (+0.97%)

After market: 12.43 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (5/8/2024, 7:00:03 PM)

After market: 12.43 0 (0%)

12.43

+0.12 (+0.97%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap882.03M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ZNTL Daily chart

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 156 full-time employees. The company went IPO on 2020-04-03. The firm develops small molecule therapeutics with differentiated product profiles for a broad range of cancers. The company is focused on pipeline of oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a B-cell lymphoma 2 (BCL-2) inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies.

Company Info

ZENTALIS PHARMACEUTICALS INC

1359 Broadway, Suite 801

New York City NEW YORK 10018

P: 12124333791

CEO: Anthony Y. Sun

Employees: 156

Website: https://www.zentalis.com/

ZNTL News

News Imagea day ago - InvestorPlaceZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024

ZNTL stock results show that Zentalis Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image2 days ago - ZENTALIS PHARMACEUTICALSZentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024...

News Image7 days ago - ZENTALIS PHARMACEUTICALSZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

News Image13 days ago - Market News VideoZentalis Pharmaceuticals Becomes Oversold (ZNTL)
News Imagea month ago - Market News VideoCommit To Buy Zentalis Pharmaceuticals At $5, Earn 6.5% Annualized Using Options
News Imagea month ago - ZENTALIS PHARMACEUTICALSZentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

Research supports azenosertib’s potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large...

ZNTL Twits

Here you can normally see the latest stock twits on ZNTL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example